← Eichor
Study identifier: NCT06923787 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study

Condition: Colon Cancer  ·  Sponsor: Institute of Oncology Ljubljana

PhasePhase 2
Planned participants100
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

There are very few data in the literature on changes in inflammatory markers when lidocaine is administered perioperatively in patients with colorectal cancer. In patients undergoing surgery for colon cancer, the aim is to conduct a double-blind placebo-controlled study to determine differences in levels of pro-inflammatory markers, postoperative pain and opioid analgesic consumption in the first two days after surgery, and the time to first postoperative bowel movement. Groups of patients receiving perioperative lidocaine infusion, high dose dexamethasone or placebo will be compared.

This description comes directly from the study's public registry record.

Talk to the study team

Eva Černe, MD  ·  0038615879844  ·  ecerne@onko-i.si

Always discuss trial participation with your own doctor first.

Locations (2)

Institute of Oncology LjubljanaLjubljana, SloveniaNot Yet Recruiting
Institute of Oncology LjubljanaLjubljana, SloveniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06923787